Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia

NCT: NCT07745621 · NOT_YET_RECRUITING

NCT IDNCT07745621
StatusNOT_YET_RECRUITING
Start Date2026-09
Completion2028-12
SponsorVivifi Medical (INDUSTRY)
First posted
Last updated

Brief Summary

The study objective is to evaluate the safety and feasibility of the Vivifi device to treat symptomatic, benign prostatic hyperplasia (BPH).

Frequently Asked Questions

What is Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia?

Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia is a clinical trial registered under NCT07745621. Current status: NOT_YET_RECRUITING.

What is the status of NCT07745621?

The current status of NCT07745621 (Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia) is: NOT_YET_RECRUITING.

When did Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia start?

Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia started on 2026-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑